Pfizer On Obamacare Rewind: No Short-Term Impact On Industry
Pfizer CEO Ian Read explains why industry has stayed on the sidelines during the current health reform debate and defends drug pricing practices during a speech to the National Press Club.
You may also be interested in...
The pharmaceutical industry will have to keep waiting for US tax reform, most likely until at least the end of 2017. President Trump plans to revisit health care reform first to generate the savings needed for "phenomenal" tax reform.
Medicaid block grant funding mechanism, which could allow states to bypass coverage requirements in the Medicaid drug rebate program, surfaces in House American Health Care Act.
Pfizer CEO Ian Read, Regeneron CEO Leonard Schleifer, Gilead CEO John Milligan and Lilly’s incoming CEO David Ricks discussed pharma’s reputation problem during the Forbes Healthcare Summit.